Viruses 2010, 2(2), 532-546; doi:10.3390/v2020532
Review

Developing Vaccines to Combat Pandemic Influenza

James S. Robertson* email and Othmar G. Engelhardtemail
Division of Virology, National Institute for Biological Standards and Control, Health Protection Agency, Blanche Lane, South Mimms, Potters Bar, EN6 3QG, UK
* Author to whom correspondence should be addressed.
Received: 25 November 2009; in revised form: 28 January 2010 / Accepted: 29 January 2010 / Published: 2 February 2010
(This article belongs to the Special Issue Influenza: Pandemics and Vaccinations)
PDF Full-text Download PDF Full-Text [202 KB, uploaded 2 February 2010 11:57 CET]
Abstract: Influenza vaccine manufacturers require antigenically relevant vaccine viruses that have good manufacturing properties and are safe to use. In developing pandemic vaccine viruses, reverse genetics has been employed as a rational approach that can also be used effectively to attenuate the highly virulent H5N1 virus and at the same time place the H5 HA and N1 NA on a background of PR8, a virus that has been used over many decades to provide high yielding vaccine viruses. Reverse genetics has also been used successfully alongside classical reassorting techniques in the development of (swine flu) pandemic A(H1N1)v vaccine viruses.
Keywords: pandemic influenza vaccines; reverse genetics; H5N1 virus; H1N1v virus

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Robertson, J.S.; Engelhardt, O.G. Developing Vaccines to Combat Pandemic Influenza. Viruses 2010, 2, 532-546.

AMA Style

Robertson JS, Engelhardt OG. Developing Vaccines to Combat Pandemic Influenza. Viruses. 2010; 2(2):532-546.

Chicago/Turabian Style

Robertson, James S.; Engelhardt, Othmar G. 2010. "Developing Vaccines to Combat Pandemic Influenza." Viruses 2, no. 2: 532-546.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert